Nuvation Bio Statistics
Total Valuation
Nuvation Bio has a market cap or net worth of $1.36 billion. The enterprise value is $1.16 billion.
| Market Cap | 1.36B |
| Enterprise Value | 1.16B |
Important Dates
The last earnings date was Wednesday, November 4, 2026, after market close.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nuvation Bio has 353.02 million shares outstanding. The number of shares has increased by 2.44% in one year.
| Current Share Class | 352.02M |
| Shares Outstanding | 353.02M |
| Shares Change (YoY) | +2.44% |
| Shares Change (QoQ) | +0.89% |
| Owned by Insiders (%) | 17.43% |
| Owned by Institutions (%) | 64.33% |
| Float | 265.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.72 |
| Forward PS | 6.26 |
| PB Ratio | 5.94 |
| P/TBV Ratio | 6.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.75 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.45, with a Debt / Equity ratio of 2.05.
| Current Ratio | 7.45 |
| Quick Ratio | 7.14 |
| Debt / Equity | 2.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.70 |
Financial Efficiency
Return on equity (ROE) is -49.09% and return on invested capital (ROIC) is -12.54%.
| Return on Equity (ROE) | -49.09% |
| Return on Assets (ROA) | -11.18% |
| Return on Invested Capital (ROIC) | -12.54% |
| Return on Capital Employed (ROCE) | -18.15% |
| Weighted Average Cost of Capital (WACC) | 11.38% |
| Revenue Per Employee | $650,745 |
| Profits Per Employee | -$438,497 |
| Employee Count | 310 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 2.72 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.99% in the last 52 weeks. The beta is 1.73, so Nuvation Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.73 |
| 52-Week Price Change | -20.99% |
| 50-Day Moving Average | 5.07 |
| 200-Day Moving Average | 5.32 |
| Relative Strength Index (RSI) | 29.81 |
| Average Volume (20 Days) | 5,259,533 |
Short Selling Information
The latest short interest is 62.00 million, so 17.56% of the outstanding shares have been sold short.
| Short Interest | 62.00M |
| Short Previous Month | 58.86M |
| Short % of Shares Out | 17.56% |
| Short % of Float | 23.35% |
| Short Ratio (days to cover) | 10.79 |
Income Statement
In the last 12 months, Nuvation Bio had revenue of $201.73 million and -$135.93 million in losses. Loss per share was -$0.39.
| Revenue | 201.73M |
| Gross Profit | 173.06M |
| Operating Income | -123.40M |
| Pretax Income | -135.93M |
| Net Income | -135.93M |
| EBITDA | -121.21M |
| EBIT | -123.40M |
| Loss Per Share | -$0.39 |
Balance Sheet
The company has $663.37 million in cash and $468.13 million in debt, with a net cash position of $195.25 million or $0.55 per share.
| Cash & Cash Equivalents | 663.37M |
| Total Debt | 468.13M |
| Net Cash | 195.25M |
| Net Cash Per Share | $0.55 |
| Equity (Book Value) | 227.98M |
| Book Value Per Share | 0.65 |
| Working Capital | 636.10M |
Cash Flow
In the last 12 months, operating cash flow was -$106.19 million and capital expenditures -$1.98 million, giving a free cash flow of -$108.17 million.
| Operating Cash Flow | -106.19M |
| Capital Expenditures | -1.98M |
| Depreciation & Amortization | 2.19M |
| Net Borrowing | 218.05M |
| Free Cash Flow | -108.17M |
| FCF Per Share | -$0.31 |
Margins
Gross margin is 85.79%, with operating and profit margins of -61.17% and -67.38%.
| Gross Margin | 85.79% |
| Operating Margin | -61.17% |
| Pretax Margin | -67.38% |
| Profit Margin | -67.38% |
| EBITDA Margin | -60.09% |
| EBIT Margin | -61.17% |
| FCF Margin | n/a |
Dividends & Yields
Nuvation Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.44% |
| Shareholder Yield | -2.44% |
| Earnings Yield | -10.17% |
| FCF Yield | -7.98% |
Analyst Forecast
The average price target for Nuvation Bio is $12.45, which is 224.22% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.45 |
| Price Target Difference | 224.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 86.04% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nuvation Bio has an Altman Z-Score of 0.7 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.7 |
| Piotroski F-Score | 3 |